Patients with metabolic syndrome are at higher risk for type 2 diabetes and for chronic kidney disease. Metformin is the oral medication of choice for the treatment of type 2 diabetes in the absence of chronic kidney disease. There is a need for another oral glucose lowering agent for use in metabolic syndrome with type 2 diabetes and chronic kidney disease. We submit the first report of erlotinib, a once-daily oral medication for the treatment of non-small-cell lung cancer associated with specific genetic mutations, appearing to eliminate the need for insulin in insulin-requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease. The mechanism by which erlotinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor may improve glycaemic control is unknown. Potential possibilities are explored.
GrundySMBrewerHBCleemanJI. NHLBI/AHA conference proceedings: definition of metabolic syndrome. Circ2004;109:433-438.
2.
LemmonMASchlessingerJ. Cell signaling by receptor tyrosine kinases. Cell2010;141(7):1117-1134.
3.
GridelliCBareschinoMASchettinoC. Erlotinib in non-small cell lung cancer treatment: current status and future development. The Oncologist2007;12(7):840-849.
4.
YangCHYuCJShihJY. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy naïve non-small-cell lung cancer receiving first line gefitinib monotherapy. JCO2008;26:2745-2753.
5.
RosellRGervaisRVergnenegreA. Erlatonib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptors (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol2011;29: (suppl; abstr 7503).
6.
CostaDBHubermanMS. Improvement of type 2 diabetes in a lung cancer patient treated with erlotinib. Diabetes Care2006;29(7):1711.
7.
AgostinoNMChinchilliVMLynchCJ. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract2011;17(3):197-202.
8.
MokhtariDWelshN. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clinical Science2010;118:241-247.
9.
BohmSHessDGillessenSBrandleM. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopaib. Diabetes Care2010;33(6):e82.
10.
LouvetCSzotG LLangJ. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci2008;105(48):18895-18900.
BallottiRLammersRScimecaJC. Intermolecular transphosphorylation between insulin receptors and EFG-insulin receptor chimerae. EMBO J1989;8(11):3303-3309.
13.
GoggSSmithU. Epidermal growth factor and transforming growth factor a mimic the effects of insulin in human fat cells and augment downstream signaling in insulin resistance. J Biolog Chem2002; 277(39):36045-36051.
14.
ShoelsonSELeeJGoldfineAB. Inflammation and insulin resistance. J Clin Invest2006;116(7):1793-1801.
15.
BorstSE. The role of TNF-alpha in insulin resistance. Endocrine2004; 23(2-3):177-182.
16.
PaniaguaRTSharpeOHoPP. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest2006;116(10):2633-2642.
17.
FraserCKLousbergELKumarR. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol2009;37(12):1435-1444.
18.
LuoQGuYZhengW. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicol Appl Pharmacol2011;251(2):130-136.
19.
JiangGZhangBB. Glucagon and regulation of glucose metabolism. AJP –Endo: 2003;284(4):E671-E678.
JonesGCMacklinJPAlexanderWD. Contraindications to the use of metformin: evidence suggests that it is time to amend the list. BMJ2003;4,326.
24.
LingJJohnsonKAMiaoZ. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos2006;34(3):420-426.
25.
BellDSHMayoMS. Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin- treated patients with non-insulin-dependent diabetes mellitus. Endoc Pract1997;3(2):73-76.
26.
BrankaKTheodoraBZTatjanaI. The effects of metformin plus sulfonylurea therapy on clinical features of the metabolic syndrome. Medicinski Pregled2010;63(9-10):611-615.
